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      Abstract 
Olanzapine is an atypical antipsychotic drug exhibiting a low incidence of 
extrapyramidal side effects. It is not only effective in treating positive symptoms of 
schizophrenia, but also more efficacious against negative and depressive symptoms than 
classical antipsychotics. Olanzapine has been recommended as the first-line drug for the 
treatment of schizophrenia. Unfortunately, a common side effect of olanzapine, namely 
weight gain, has also been observed. A comprehensive literature analysis revealed that 
olanzapine induced higher weight gain than most other antipsychotics, only second to 
clozapine. The incidence of olanzapine-induced weight gain and related diseases, such as 
diabetes and cardiovascular diseases, is higher than that of the general population. These 
unwanted side effects have decreased the adherence to treatment. Many clinical 
observations and preliminary animal studies have attempted to elucidate the possible 
mechanism involved. To date, the mechanism for olanzapine-induced weight gain 
remains unclear. 
This research project utilizes an animal model to investigate the possible 
mechanism of olanzapine-induced weight gain. The specific research objectives include: 
1) does olanzapine affect feeding behavior; 2) can olanzapine influence the levels of 
glucose and triglyceride; 3) are cytokines, such as insulin, leptin, and TNF-α involved in 
olanzapine-induced weight gain; 4) how does olanzapine affect adipose tissue? 
An olanzapine-induced weight gain animal model has been established in the 
present investigation. An increase in food and water intake and increase in fat deposition 
accompanied with weight gain after treatment were observed. No significant increase in 
levels of glucose and triglyceride was detected. The changes of insulin and leptin levels 
 ii
in blood suggest that olanzapine may affect the endocrine system. A dramatic 
morphological alteration of adipose tissue by olanzapine was serendipitously observed. 
Immunohistochemical staining revealed that olanzapine stimulated collagen VI 
expression and deposition in the extracellular matrix suggesting that adipocyte 
differentiation may be enhanced. The effect of olanzapine on fat deposition might play a 
critical role in olanzapine-induced weight gain. The data from adipose tissue have 
provided a new clue on future research in understanding the mechanism of olanzapine-
induced weight gain. Due to limitation of small number of animals and relatively short 
term of treatment, a large variation in groups diminished the power of analysis regarding 
the effects of olanzapine related to weigh gain.  
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1. Introduction 
1.1 Schizophrenia and antipsychotics 
Schizophrenia is a major psychiatric illness. The symptoms of this disease include 
positive and negative features. Delusion, hallucinations and thought disorder are positive 
symptoms; negative symptoms include withdrawal and flattening of emotional responses. 
The cause of schizophrenia is still unclear. Few animal models have been established for 
schizophrenia research. Indirect evidence from human and experimental animals suggests 
that neurochemicals in the brain are involved in the symptoms of schizophrenia (Rong et 
al, 2003). 
The dopamine hypothesis of schizophrenia was proposed in 1965. Amphetamine, 
a chemical capable of releasing dopamine in the brain, can produce acute schizophrenic-
like behaviour symptoms in human, and can also exacerbate schizophrenic symptoms. In 
animals, dopamine-releasing agents cause a type of stereotypic behaviour resembling the 
repetitive behaviours seen in schizophrenic patients. Dopamine receptor agonists exhibit 
similar effects in animals. Dopamine antagonists and drugs that block neuronal dopamine 
storage can control positive symptoms of schizophrenia and amphetamine-induced 
behaviour changes. The antipsychotic efficacy of dopamine antagonists is correlated with 
their activity in blocking the dopamine D2 receptors (Strange, 2001). 
Several neurotransmitters, especially those interacting strongly with dopamine 
pathways, such as 5-HT, norepinephrine and glutamate, seem also to be involved in the 
etiology of schizophrenia. The hypothesis that 5-HT dysfunction may be involved in 
schizophrenia is based on the observation that lysergic acid diethylamide (LSD) also 
produces schizophrenic-like symptoms. The main behavioural effect caused by LSD is 
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hallucinations. As a 5-HT agonist, LSD mainly acts on 5-HT2 receptors in the CNS. 5-HT 
has a modulatory effect on dopamine pathways. Many so-called “atypical” antipsychotic 
drugs work as antagonists both on 5-HT and dopamine receptors. They produce fewer 
extrapyramidal side effects (EPS) than those drugs that mainly targeting the 
dopaminergic system. It was postulated that blocking 5-HT2 receptors may counteract the 
undesirable side effects related to D2  receptor antagonists (Busatto et al., 1997).  
The neurochemical hypothesis of schizophrenia is supported by indirect evidence. 
Although it is oversimplified, it provides fundamental knowledge for understanding the 
action of antipsychotic drugs.  
  Antipsychotic drugs available have been classified as “typical” or “atypical”. 
These terms are not clearly defined. Generally, the distinction rests on the incidence of 
extrapyramidal side effects, efficacy in treatment–resistant groups of patients, and 
efficacy against negative symptoms.  
All antipsychotic drugs exhibit antagonistic effects on D2 receptors. Clinical 
efficacy of antipsychotic agents is achieved when approximately 80% of D2 receptors are 
occupied. Blocking function of D2 receptor by antipsychotics can be measured by in vitro 
experiments, i.e., assessment of the ability to inhibit the binding of a radioactive D2 
antagonist to brain membrane fragments. The effect of D2 antagonists can also be 
measured by assessing the inhibition of amphetamine-induced stereotypic behaviour in 
animals. Different types of drugs show different affinities to dopamine receptors. Some 
are highly selective for D2 receptors; some are relatively non-selective between D1 and 
D2 (Seeman, 1987). 
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Antipsychotic drugs cause several types of unwanted effects related to their 
pharmacological profiles. Due to the blockade of D2 receptors, EPS are the most common 
side effects. The effects include movement disorders, e.g. acute dystonias and tardive 
dyskinesia. Acute dystonias are involuntary movements, tremor and rigidity. They occur 
in the first few weeks and can be reversed by stopping treatment. Tardive dyskinesia 
develops after months or years in 20-40% of patients treated with typical antipsychotic 
drugs. This is a serious side effect since it is irreversible, untreatable, and can worsen 
when the antipsychotic-treatment is stopped, which can disable the patient. The syndrome 
comprises involuntary movement of face and tongue, and also of the trunk and limbs. The 
occurrence of this syndrome depends on the duration and dosages of the drugs, and the 
age of the patients (Klawans et al., 1988). One hypothesis about tardive dyskinesia is that 
it is related to gradual increase in the density of D2 receptors via up-regulation in the 
striatum. Another theory is that chronic inhibition of dopamine receptors enhances 
catecholamine and/or glutamate release in the striatum. Glutamate has been reported to 
cause excitotoxic neurodegeneration (Casey, 1995). Other common side effects caused by 
antipsychotic drugs include sedation, hypotension and weight gain.  
Antipsychotic drugs can improve the acute symptoms of schizophrenic patients 
and long-term treatment can prevent the recurrence of symptoms and lead to a more 
normal life of the patients. However, it has been found that typical antipsychotics are 
only effective in about 60%-70% of patients. Those patients who do not respond to drugs 
are known as “antipsychotic-resistant”. Although these drugs are efficient in controlling 
positive symptoms, they are not effective in relieving negative symptoms. Compared to 
typical antipsychotics, atypical drugs are capable of overcoming, to some degree, these 
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shortcomings. They are not only effective in treating positive symptoms of some 
“antipsychotic-resistant” patients, but also improve negative symptoms, as well as 
decreasing the risk of EPS and tardive dyskinesia dramatically (Rang et al, 2003). 
1.2 Atypical antipsychotics and weight gain 
It has been reported that atypical antipsychotics are capable of causing weight 
gain, even obesity, in patients in comparsion to typical antipsychotics. Obesity and 
weight gain are well known risk factors for hypertension, type II diabetes, coronary heart 
disease, stroke, gallbladder disease, respiratory problems and even some types of cancer 
in general population (Allison et al., 1999). Indeed, it has been observed that atypical 
antipsychotic-treated obese patients are more likely to develop type-II diabetes and 
cardiovascular diseases. Severe weight gain and obesity-related diseases cause patients to 
discontinue their treatment. A retrospective analysis showed that the degree of weight 
gain ranged from 0.04 kg for ziprasidone to 4.45 kg for clozapine, estimated by the 
random effects regression at 10 weeks (figure1.2.1). This data clearly indicated that 
atypical antipsychotics might have more tendency to cause weight gain than most of the 
classical antipsychotics (Allison et al, 1999). 
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Figure 1.2.1 Weight change induced by antipsychotics after 10 weeks on standard drug 
doses, estimated from a random effect model. (Data was adapted from Allison et al., 
1999)  
 
 Regarding antipsychotic-induced weight gain, a positive correlation between body 
weight gain and the dosage of clozapine has been reported. A dose-dependent effect of 
olanzapine on weight gain has also been observed (Russell et al., 2001). Other potential 
factors related to antipsychotic-induced weight change have been noticed, such as 
patients with low pre-treatment body mass index, young age, certain psychiatric disorders 
or using mood stabilizers. The association between weigh gain and these factors needs 
further studies (Russell et al., 2001). Some adverse metabolic effects of antipsychotics 
have also been observed in overweight patients, including glucose and lipid 
abnormalities, hyperinsulinaemia – indicating insulin resistance, and hyperleptinaemia 
(Melkersson et al., 2004; Meyer, 2001; Russell et al., 2001).  
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  The mechanism of antipsychotic-induced weight gain is still unclear. Some 
hypotheses focus on the neurotransmitters related to feeding behaviour and weight 
regulation. Dopamine and serotonin can decrease feeding behaviour in animal models, 
the serotonin antagonists stimulate food intake (McIntyre et al., 2001a). Histamine 
receptors are involved in drinking behaviour in rats. It is postulated that blocking the 
receptors of these neurotransmitters by antipsychotics may be involved in the mechanism 
of weight gain (McIntyre et al., 2001b; Zimmermann et al., 2003). However, an analysis 
of serotonin receptors failed to establish a correlation between weight gain induced by 
clozapine, olanzapine, risperidone, haloperidol, and sertindole with 5-HT2C receptor 
affinity (McIntyre et al., 2001a).  
Severe weight gain induced by antipsychotics also changes the levels of hormones 
related to weight regulation, such as insulin and leptin. The change in hormones may 
affect the sensitivity of satiety neurons in the lateral hypothalamus, and metabolism in the 
human body (Friedman, 1998). The hyperinsulinemia observed in antipsychotic-treated 
patients may lead to hyperlipidaemia. Hyperglycaemia and diabetes will develop due to 
insulin resistance. Leptin, the hormone produced by adipocytes, suppresses appetite 
through its receptor in the hypothalamus, and also regulates lipid metabolism in 
peripheral tissue. Hyperleptinaemia in antipsychotic-treated patients may indicate leptin 
resistance. This resistance may result in an increase in appetite and lipid abnormality, 
exacerbating weight gain (Melkersson et al., 2004).  These hypotheses need further study. 
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1.3 Olanzapine 
 
 
 
 
 
 
Figure 1.3.1 The chemical structures of olanzapine and clozapine 
 
Olanzapine is a thienobenzodiazepine. Its structure is similar as that of clozapine, 
which is the archetypal atypical antipsychotic (figure 1.3.1) (Green, 1999; Trevitt et al., 
1999). Experiments in vitro have shown that olanzapine affects key receptors, which are 
believed to be related to schizophrenia. The binding profile indicates that olanzapine has 
high affinity for 5-HT2A, 5-HT2B, 5-HT2C and 5-HT6, and histamine (H1) receptors, as 
well as a moderate affinity for D2 and acetylcholine muscarinic receptors, and a low 
affinity for β-adrenergic receptors (Stephenson et al., 1999; Trevitt et al., 1999). 
Olanzapine also interacts non-selectively with other dopamine receptors and 5-HT1, 5-
HT3, 5-HT4 and 5-HT7 receptors. The limbic selectivity of olanzapine reflects its atypical 
antipsychotic properties. c-fos is an early oncogene and its expression was used as a 
marker for neuronal activity. Olanzapine induces c-fos expression in the nucleus 
accumbens, which also can be increased by other atypical antipsychotics, and usually 
correlates with efficacy in treating positive symptoms. Olanzapine also induces c-fos in 
the prefrontal cortex, which might be related to its efficacy in treating negative 
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symptoms. These effects are similar to what has been observed with clozapine 
(Stephenson et al., 1999).   
Behavioural and pharmacological studies of olanzapine confirm that it interacts 
with dopamine, serotonin and muscarinic receptors, and exhibits clozapine-like profiles, 
including mesolimbic selectivity, blocking 5-HT receptors at a lower doses than that for 
dopamine receptors, and inhibiting the conditioned avoidance response (indication of 
antipsychotic efficacy) at lower dose than that required to induce catalepsy (indication of 
EPS) (Moore et al., 1997). Double blind clinical studies show that olanzapine is highly 
efficacious in treating psychotic symptoms, while it has low liability to induce tardive 
dyskinesia or parkinsonism (Trevitt et al., 1999). In contrast to clozapine, olanzapine 
does not cause agranulocytosis in patients. Although clozapine has clear advantages over 
traditional antipsychotics, and causes less extrapyramidal side effects in patients, the 
agranulocytosis can be very serious and could be life threatening.  Therefore, olanzapine 
has been considered as the first line drug and widely used in treatment of psychosis 
(Green, 2000; Stephenson et al., 1999). 
Unfortunately, olanzapine also exhibits a common unwanted side effect, namely, 
increase in weight. Several clinical reports have shown that olanzapine-induced weight 
gain is accompanied with increased body fat, serum levels of glucose, triglyceride, 
insulin and leptin (Eder et al., 2001; Melkersson et al., 2000; Osser et al., 1999). Allison’s 
report show that among different atypical antipsychotics, olanzapine cause the second 
highest degree of weight gain at 10 weeks using a random effects model, only lower than 
the weight gain caused by clozapine (Allison et al., 1999). Based on the definition from 
Federal Drug and Food Administration (U.S.A) that weight gain induced by any given 
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drug is an increase in body weight of more than 7% before treatment, a study showed that 
29% of patients with olanzapine obtained 7% or more increase in body weight, while 
only 25% of patients treated with quetiapine, 18% with risperidone, and 9.8% with 
ziprasidone did (Muller et al., 2004). Investigations also show that olanzapine 
significantly increases the risk of developing diabetes over conventional antipsychotics 
(Koro et al., 2002). McIntyre and colleagues reported that Zolar retrospectively assessed 
396 antipsychotic-treated patients and the result indicated that olanzapine tends to cause a 
higher incidence of type II diabetes than other antipsychotics. In this report, the 
prevalence of type II diabetes in the general population is 5%-7%. However, it was 
estimated that the incidence of type II diabetes caused by olanzapine was 11%, while 
6.6% by haloperdol, 6% by risperidone, and 4.5% by fluphenazine (McIntyre et al., 
2001b). Excess weight gain and obesity in these patients would increase the risk of 
hypertension, chronic cardiovascular disease and cancer. This side effect also causes 
distress in patients, affects their self-esteem and decreases treatment adherence. 
 
1.4 Obesity  
Obesity is defined as the state of severe increase in body weight, more specially 
adipose tissue, which impairs the health of individuals. A simple method to measure 
obesity is to calculate the body mass index (BMI). It is described as the weight in 
kilograms divided by the square of the height in metres (kg/m2). The World Health 
Organization (WHO) defines the classification of BMI (table1.4.1) (Leong et al., 1999; 
Spiegelman et al., 2001). It has been reported that one-third of American people are 
obese with BMI more than 25 kg/m2. Obesity has become a worldwide health problem, 
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and is a well-known risk factor for cardiovascular, respiratory, gastrointestinal disorders, 
diabetes and some types of cancer (McIntyre et al., 2001a; Spiegelman et al., 2001).  
 Table 1.4.1 The classification of body mass index (BMI) 
Classification                              Body Mass Index 
Normal                                                   18.5-24.9 
Pre-obese (over-weight)                         25.0-29.9 
Obese, class 1                                         30.0-34.9 
Obese, class 2                                         35.0-39.9 
Obese, class 3                                          ≥ 40.0 
                                                                    (table was adapted from Leong et al., 1999) 
Body weight is maintained by the balance of energy intake and energy 
expenditure. A person gains weight when he is in positive energy balance (figure 1.4.1). 
The mechanisms of regulating in energy balance and body weight include control of the 
central nervous system (CNS), neuropeptides and cytokines (McIntyre et al, 2001; 
Spiegelman et al., 2001). 
     Energy intake                                                            Energy expenditure       
 
     Feeding                                                                          Physical activity                                
                                                                                             (Basal metabolism &  
                                                                                               Adaptive thermogenesis) 
 
Figure 1.4.1 Component of the energy balance system (figure was adapted from 
Spiegelman et al., 2001). 
 
The CNS influences energy balance by affecting feeding and physical behaviour 
and by affecting the neuroendocrine system. The hypothalamus is a critical region of the 
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brain related to the regulation of food intake. The monoamine activity in this region is 
thought to be responsible for the regulation. Dopamine decreases feeding behaviour in 
animal models (Floris et al., 2001). Serotonin also decreases food intake, suggesting that 
serotonin antagonists stimulate energy intake. 5-HT2C receptor-deficient mice have been 
shown to be overweight and to overeat (Tecott et al., 1995). Histamine (H1, H2, H3) 
receptors in the hypothalamus are well known to be involved in mediating drinking 
behaviour. Histamine antagonism increases weight by stimulating appetite (McIntyre et 
al., 2001b). Neuropeptides and cytokines have also been shown to affect weight 
regulation. These peptides, such as insulin, leptin and tumor necrosis factor α (TNF-α), 
have been demonstrated to be involved in the regulation of glucose and general 
metabolism (McIntyre et al., 2001a).  
1.4.1 Insulin  
Insulin is the most potent hormone in promoting synthesis and storage of 
carbohydrates, lipids and proteins; and in inhibiting their degradation in adipose tissue, 
liver and skeletal muscle. Plasma insulin levels rise after eating. It stimulates glucose 
uptake and conversion to glycogen and/or triglycerides in muscle and adipose tissue. 
While insulin-mediated glycogen synthesis is increased in muscle and adipose tissue, 
insulin-dependent gluconeogenesis and glycogenolysis are suppressed in liver. Insulin 
also increases lipoprotein lipase activity in adipose tissue to clear the triglyceride-rich 
lipoproteins in plasma and inhibits adipocyte hormone-sensitive lipase activity to 
dramatically reduce the release of free fatty acids from adipose tissue. Insulin is the only 
known major hormone that promotes energy storage and inhibits energy utilization (Ruan 
et al., 2003; Saltiel et al., 2002). 
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Saltiel and colleagues (Saltiel et al., 2002) reviewed insulin signal pathway. 
Insulin’s action on glucose metabolism is mediated by initiating the activity of the insulin 
receptor (IR), a tyrosine kinase. After insulin binds, the receptor undergoes 
autophosphorylation. With the increase in kinase activity, it subsequently phosphorylates 
several substrates, including the insulin receptor substrate (IRS), Gab-1, Shc, Cbl and 
adapter molecule containing PH and SH2 domains (APS), leading to activation of 
different pathways. Regarding the regulation of glucose transport, there are at least two 
signalling pathway models. One pathway that is initiated by IRS is PtdIns 3-kinase 
(PI3K) dependent. This kinase triggers a cascade of phosphorylation events. 
Phosphorylated IRS initiate a cascade of the PI3K pathway, including the activation of 
Akt and/or protein kinase C (PKC). Subsequently, the activated glucose transporter 4 
(Glut4), phosphorylated by activated Akt and PKC, is translocated to the plasma 
membrane and promotes glucose transport into the cell. Insulin may also stimulate the 
cytoskeletal rearrangement for Glut4 location. Insulin receptor also phosphorylates Cbl 
and APS, which trigger a PI3K independent pathway to regulate glucose transport (Saltiel 
et al., 2002). Therefore, any factor influencing the sensitivity of the insulin receptor will 
affect the metabolism of glucose. 
  Insulin also affects insulin-sensitive enzymes, which are involved in glucose 
metabolism. Insulin increases the concentration of enzymes for glycolysis, such as 
hexokinase, phosphofructokinase-1 and pyruvate kinase.  Insulin affects adipose cells by 
controlling the level of fatty acids by storing and hydrolysing triglyceride. It has been 
shown recently that insulin may partly regulate this process in promoting intracellular 
fatty acid transporters FATP1 and FATP4 to the plasma membrane. This raises the 
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intracellular fatty acids that are in turn converted to fatty acyl CoA. Insulin also increases 
lipoprotein lipase activity, resulting in the release of fatty acid from dietary fat to 
adipocytes, decreases to lipolysis of triglycerides stored in fat cells, and increases the 
esterification of fatty acids to triglycerides (Czech, 2002). 
Insulin receptors not only exist in peripheral target tissues, but are also found in 
the hypothalamus. The PI3K pathway in the hypothalamus is activated after 
intracerebroventricular injections of insulin (Niswender et al., 2003a). Food intake-
lowering effects of insulin are reversed by intracerebroventricular infusion of PI3K 
inhibitors, thus supporting a CNS role for insulin in the regulation of feeding behaviour 
(Niswender et al., 2003a; Niswender et al., 2003b). 
Insulin resistance has been observed in human forms of obesity and diabetes. A 
hypothesis of insulin resistance is related to the high fat feeding behaviour. Intracellular 
insulin signalling pathway has been found to be impaired in high fat feeding models and 
intravenous lipid infusion models. Increased intracellular fatty acids may activate a 
serine/threonine kinase, but not tyrosine kinase, cascade, leading to the phosphorylation 
of serine/threonine sites on IRS. Serine-phosphorylation reduces the ability of IRS to 
interact with PI3K, thus failing to activate glucose transport and other downstream events 
(Niswender et al., 2003b; Shulman, 2000). As a consequence, cells become resistant or 
lose the response to the action of insulin even though enough insulin is produced. Higher 
levels of insulin are therefore required to regulate glucose metabolism. This resistance 
occurs often in people with obesity, type II diabetes, or high levels of fat in the blood. 
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1.4.2 Leptin  
Leptin is an adipocyte-derived protein. It was first cloned in ob/ob mouse that 
have genetic deficiency of leptin genes. Leptin can exert satiety effects by limiting 
feeding behaviour and increasing energy expenditure. It is mainly synthesized in white 
adipose tissue. Chronic central leptin infusion in rats has been found to decrease food 
intake and as the result the body weight of these animals gradually decreased (Auwerx et 
al., 1998). 
Leptin achieves its metabolic function through specific receptors located in the 
hypothalamus, the feeding centre, and in peripheral tissues, notably adipose tissue, liver, 
skeletal muscle and kidney (Auwerx et al., 1998; Cohen et al., 1996; Muoio et al., 2002). 
The receptors transmit the leptin signal to activate Janus kinase (JAK), a signal 
transducer and activator of transcription-3 (STAT3)-dependent pathway (Vaisse et al., 
1996; Zabeau et al., 2003). The central leptin receptors bind leptin which is transported in 
blood and crosses the blood-brain barrier by a saturable transport system. Studies on 
leptin receptor signalling through the JAK-STAT3 signal pathway demonstrated that the 
phosphorylated leptin receptors and phosphorylated STAT3 remained elevated in the 
hypothalamus during chronic central leptin infusion, initiating a decrease in food intake 
(Pal et al., 2003). Several candidate effectors related with feeding behaviour and energy 
metabolism are thought to be regulated by leptin. The hypothalamic arcuate nucleus 
contains two primary types of neurons which express leptin receptors. Leptin activates 
the proopiomelanocortin (POMC) neuron to secret an anorexic neuropeptide, α-
melanocyte stimulating hormone (α-MSH), resulting in reduction of food intake and an 
increase in energy expenditure. In contrast, leptin also reduces the food intake by 
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suppressing the secretion of the neuropeptide Y (NPY)/agouti related protein (AgRP) in 
neurons which potently stimulate food intake (Auwerx et al., 1998; Niswender et al., 
2003b). 
Leptin also affects lipid metabolism related to the activation of the JAK/STAT 
signal pathway in the peripheral system, such as adipose tissue, liver or skeletal muscle.  
Several downstream target including SREBP1, PPARγ and PPARα, are regulated. In 
liver, leptin suppresses mRNA expression of SREBP1 and PPARγ, thereby blocking their 
transcriptional activation involved in cholesterol synthesis, and also blocking lipogenesis 
and glycerolipid synthesis. Leptin increases the expression of PPARα, an activator of 
fatty acid oxidation and uncoupling proteins (UCPs). The increase in UCP activity can 
promote thermogenesis and decrease cellular levels of ATP (Muoio et al., 2002). Leptin 
stimulates the rate of lipolysis and increases lipid oxidation, i.e. increasing the expression 
of enzymes of fatty acid oxidation, such as carnitine palmitoyl transferase-1 (CPT-1) and 
acyl CoA synthase (Wang et al., 1999). Leptin also inhibits the activity of acetyl-CoA 
carboxylase, which is a rate-limiting enzyme in fatty acid synthesis. All these effects of 
leptin result in reducing intercellular fatty acid and triglyceride concentrations (Auwerx 
et al., 1998; Palou et al., 2000). 
Both leptin and insulin exert critical effects on glucose and fatty acid metabolism. 
Although these two cytokines, and the receptors they act on, are totally different, 
evidence suggests that there is a cross talk between these two factors. With the infusion 
into brain, leptin, which acts through the JAK-STAT signal pathway, also increases PI3-
Kinase activity (Zhao et al., 2002). Infusion of an inhibitor of this enzyme can block 
leptin-induced anorexia (Niswender et al., 2001). Leptin is also capable of activating the 
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IRS-PI3K pathway in adipose tissue and liver to exert insulin-like function to some 
degree (Kim et al., 2000). The cross-talk between insulin and leptin in the CNS and 
peripheral tissue cells indicate that factors, which affect PI3K pathway related to insulin 
and leptin, may alter feeding behaviour and nutrient metabolism. 
Since leptin regulates feeding behaviour and energy balance, it becomes very 
important in the study of obesity. It was thought that deficiencies in leptin production or 
leptin receptor in ob mice might also be found in obese humans. However, neither 
deficiencies in leptin production nor mutations in the leptin gene or the leptin receptor 
gene were detected in most obese humans (Palou et al., 2000). Therefore, the alterations 
in the transport of leptin to the CNS or leptin resistance may take place in obesity. High 
serum leptin levels in obese humans are not matched by the levels of leptin in the 
cerebrospinal fluid, suggesting that a decrease in leptin transport may occur.  Meanwhile, 
since both insulin and leptin can active the PI3K pathway, and leptin-reduced food intake 
is PI3K dependent, it is hypothesized that the mechanism of leptin resistance, or 
hyperleptinemia in human obesity might be similar to that of insulin resistance caused by 
uncorrected phosphorylation of PI3K (Niswender et al., 2001). 
1.4.3 Tumor necrosis factor-α (TNF-α) 
  TNFα was first identified in the serum of endotoxin-treated mice and is 
responsible for the hemorrhagic necrosis of tumors (Argiles et al., 1997; Old., 1985). A 
26 KDa membrane-bound monomer precursor protein cleaved by TNF-α converting 
enzyme to form mature secreted TNF-α trimer. Two TNF-α receptors, type I (p55), a 55-
KDa protein, and type II (p75), a 75-KDa protein, have been identified. They mediate 
TNF-α signal transduction by forming protein complexes with cytoplasmic adaptor 
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proteins (Ruan et al., 2003).  TNF-α not only exerts a variety of effects on growth 
promotion, growth inhibition, cytotoxicity and inflammation, but also plays a critical role 
in regulation of metabolism, immune responses and appetite behaviours (Aggarwal et al., 
1996). Different cell types, such as macrophages and monocytes, adipocytes and muscle 
cells express TNF-α(Saghizadeh et al., 1996).  
Studies have indicated that there is a link between TNF-α and obesity. mRNA 
expression and production of TNF-α protein are increased in adipose tissue of obese 
humans. The plasma concentration of soluble TNF-α receptors (TNFR) was also found to 
be increased in obese subjects. Body weight reduction in these subjects is accompanied 
with a decrease in mRNA expression of TNF-α (Hauner et al., 1998; Hotamisligil et al., 
1995).  
Obesity is frequently linked to insulin resistance and type-II diabetes.TNF-α 
blocked insulin-mediated glucose uptake in cultured cells (Hotamisligil et al., 1994a). 
TNF-α downregulated Glut4 mRNA levels in cultured adipocytes and myocytes 
(Stephens et al., 1997). It also reduced the catalytic activity of the insulin receptor. This 
effect was mediated through its ability in reducing the insulin-stimulated insulin receptor 
autophosphorylation and IRS-1 phosphorylation (Hotamisligil et al., 1994b). 
Neutralization of TNF-α with intravenous administration of TNFR-IgG in Zucker fa/fa 
rats dramatically improved insulin sensitivity and increased tyrosine phosphorylation of 
the insulin receptors and IRS-1 (Hotamisligil et al., 1994a, 1994b). In an in vitro study, 
TNF-α was shown to induce sustained suppression of cytokine signalling protein-3 
(SOCS-3) production. This protein could decrease insulin-induced IRS-1 tyrosine 
phosphorylation and its association with the regulatory subunit, p85, of PI-3K. Therefore, 
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it was suggested that SOCS-3 might be a mediator in the insulin resistance developed 
with TNF-α treatment (Grimble, 2002).    
Leptin has also been found to share sequence and structural homology with 
cytokines in the interleukin-6 (IL-6) family and their receptors. It is not surprising that it 
may also be involved in immunoactivity related to TNF-α. It has been known that high 
concentrations of leptin are seen in obese and diabetic patient. Many studies indicated 
that TNF-α might stimulate leptin secretion in adipocytes. TNF-α increased leptin 
secretion in a dose-dependent manner in primary cultures of epididymal adipocytes. An 
increase in steady-state leptin gene expression was observed following exposure of TNF-
α. The mechanism how TNF-α affects leptin production is still unclear. TNF-α receptors 
may also mediate inflammatory hyperleptinemia by initiating a diverse signalling 
pathway after ligand binding. Studies have shown that p55 TNFR was essential for TNF-
α to stimulate leptin secretion (Finck et al., 2000; Finck et al., 2002; Moller, 2000; Sethi 
et al., 1999). The links between increased levels of TNF-α and hyperleptinemia in 
obesity needs further clarification.           
TNF-α can affect glucose, protein and lipid metabolism. It has been reported that 
prolonged infusion of TNF-α impaired insulin-mediated whole body glucose disposal 
and insulin-stimulated suppression of hepatic glucose output in rats (Moller, 2000).  
Downregulation of Glut4 mRNA expression and decrease in kinase activity of insulin 
receptor by TNF-α also impaired glucose homeostasis (Stephens et al., 1997). TNF-α 
could stimulate lipolysis by inhibiting the action of lipoprotein lipase, an enzyme 
responsible for the hydrolysis of lipoprotein triglycerides and for the entry of fatty acids 
into adipocytes. TNF-α also increased the activity of hormone-sensitive lipase, a rate-
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limiting enzyme of lipolytic pathways (Argiles et al., 1997). These actions resulted in the 
elevation of serum lipid levels, such as triglyceride and free fatty acid (FFA) and a 
decrease in HDL cholesterol (Grimble, 2000; Ruan et al., 2003). Increased levels of FFA 
have been demonstrated to reduce glucose uptake and metabolism in rat heart and 
diaphragm muscles, and to inhibit insulin signalling and glycogen synthesis in muscle. 
Increased FFA oxidation also elevated the ratios of mitochondrial acetyl-CoA: CoA and 
NADH: NAD+, resulting in impaired insulin-mediated glucose utilization. Therefore, 
TNF-α may influence the progress of insulin resistance by changing FFA levels (Ruan et 
al., 2003; Sethi et al., 1999) 
 
1.5 Olanzapine-induced weight gain and cytokines 
Olanzapine has been reported to induce dramatic weight gain in some patients, 
accompanied with elevated levels of glucose, lipid, insulin and leptin. As the hormones 
involved in the regulation of feeding behaviour and nutrient metabolism, the 
abnormalities of insulin and leptin will exert direct effects on glucose and lipid 
metabolism. These abnormalities may give rise to a development of insulin-resistance, 
resulting in drug-induced diabetes and increase the risk of cardiovascular disease.   
Several clinical reports have shown that blood levels of TNF-α and/or TNFR are 
increased in antipsychotic-treated patients. Clozapine, which can cause obvious weight 
gain in patients, induces a significant increase in plasma levels of TNF-α, p55 TNFR and 
p75 TNFR after several weeks treatment (Pollmacher et al., 1996). Olanzapine, a 
structural analogue of clozapine, has also been reported to increase plasma level of TNFR 
in treated patients (Schuld et al., 2000). Atypical antipsychotic drugs can induce obesity 
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and increase the risk of developing type II diabetes in patients. The role of TNF-α needs 
to be evaluated in olanzapine-induced weight gain.   
Several recent studies also showed that olanzapine increase feeding behaviour in 
animals (Arjona et al., 2004; Lee et al., 2002; Pouzet et al., 2003). A report attempted to 
analyze the relationship between the change of neurotransmitters and food intake. The 
neurotransmitters include dopamine, serotonin and their metabolites (Arjona et al., 2004). 
However, the mechanism of olanzapine-induced weight gain and the change of 
metabolism associated with weight gain are still unclear.  
 
1.6 Hypothesis 
It is hypothesized that increased level of TNF-α induced by olanzapine may be 
involved in the insulin and leptin resistance. In the brain insulin and leptin resistance may 
influence the feeding behaviour related to weight gain. In peripheral tissue, insulin and 
leptin resistance would lead to glucose and lipid abnormality as well as affecting 
adipocyte differentiation. 
 
1.7 Objectives 
The objectives of this study are to investigate the effects of olanzapine on feeding 
behaviour and to assess the potential role of insulin, leptin and TNF-α activities in 
olanzapine-induced weight gain and to examine any alteration of adipocytes in an animal 
model. The study is aimed to contribute to our understanding of the roles of cytokines in 
olanzapine-induced weight gain and to develop strategies to alleviate such unwanted side 
effects.  
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2. Materials and methods 
 
2.1 Animal treatment 
Female Wistar rats (200 - 250g, Charles River Canada, Montréal, Québec) were 
housed under a 12 h light-dark cycle at a temperature of 19-20oC with free access to both 
food and water. All procedures involving animals were performed in accordance with the 
Canadian Council on Animal Care Guidelines and approved by University of 
Saskatchewan’s Committee on Animal Care and Supply. After 1 week of acclimatization, 
rats were randomly divided into different groups. There were five animals in each group. 
Different concentrations of olanzapine were administrated via drinking water. Control 
group was treated with vehicle; other groups were treated with olanzapine at 0.003 
mg/ml, 0.006 mg/ml, 0.01 mg/ml, 0.02 mg/ml, 0.03 mg/ml and 0.04 mg/ml. In another 
study, olanzapine (3 mg/kg) was given by oral administration.  The average water intake 
by the rats was between 30 ml to 40 ml/day; therefore, the daily dosages of olanzapine 
treated rats were estimated between 0.3 mg/kg to 6 mg/kg.  The food was ground rat 
chow mixed with canola oil. The weight ratio of rat chow to oil was 5:1 (5 ground chows: 
1oil).  
 
2.2 Drug 
  Olanzapine (Eli Lilly, Toronto, Canada) was dissolved in a small amount of 2% 
acetic acid and then was brought up to volume with distilled water, and neutralized with 
10 M NaOH (pH = 6.0-7.0). Olanzapine tablets were also used. Inactive ingredients are 
carnuba wax, colour mixture white, hydroxypropyl cellulose, lactose and other inactive 
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component. For preparation of olanzapine solution, the tablets were dissolved in 2% 
acetic acid and filtered through 0.2 µm HT Tuffryn® membrane syringe filter. The 
filtered solution was diluted to the desired concentrations. The purity of olanzapine was 
determined by HPLC. It was not necessary to add an antioxidant to preserve olanzapine 
stability in samples as it was found to be stable under these conditions (Dusci et al., 
2002). The HPLC system basically consisted of a solvent delivery pump, an automatic 
sample injector, a separation system, and an ultraviolet detector operated at 270 nm 
(figure.2.2.1). The separation system is consisted of a reverse phase C18 column, and a 
mobile phase of 14% acetonitrile in phosphate buffer (table 2.2.1), which was pumped at 
a flow-rate of 1 ml/min.  Standard solution of olanzapine was prepared at a concentration 
of 0.03 mg/ml in water. 50 µl of olanzapine standard or olanzapine tablet solution was 
injected into the column. The stability of olanzapine upon storage was also assessed by 
the same method. Olanzapine solutions kept for 1 day at 4oC, or 3 and 7 days at room 
temperature were tested.  
 
 
       (1)                (2)                  (3)               (4)               (5)                         (6) 
 
 
 
 
Figure 2.2.1 HPLC system. (1) mobile phase, (2) pump, (3) pre-column, (4) injector, (5) 
analytical column, (6) detector  
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Table 2.2.1. Preparation of 14% acetonitrile 
Chemical compound Final concentration Amount in 1L 
acetonitrile 14% 140 ml 
H3PO4 0.25% 2.15ml 
triethylamine 0.05% 0.43ml 
 
 
2.3 Food intake, water intake and body weight measurement 
The rat was housed individually for feeding measurement. Individual food and 
water consumption were assessed and recorded once a week. Food was provided in a 
bowl in each cage. The body weight of individual animals was assessed and recorded 
once a week.    
  
2.4 Sample collection 
2.4.1 Rat plasma  
After fasting 12 hours, blood was collected from tail vein of the rats. 2% 
xylocaine gel was applied to the rat’s tail for skin anaesthesia. The blood was collected 
by knife cut. Heparin was used as the anticoagulant. The blood sample was centrifuged at 
2,000 g, at 4oC for 10 minutes. The supernatant was collected as rat plasma. All samples 
were stored at –20oC for further study. 
2.4.2 Adipose tissue 
 Rats were anesthetised by an intraperitoneal injection of chloral hydrate at 40 
mg/kg.  The abdomen was rinsed with ethanol, and the skin was widely incised. The 
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subcutaneous adipose pad was collected, weighed and frozen on dry ice quickly. The 
abdomen was then opened and the abdominal adipose tissue was also collected, weighed 
and frozen in dry ice. All the samples were stored at –70oC until further analysis.          
 
2.5 Histochemistry 
2.5.1 Hematoxylin stain 
The slides were coated with 1% poly-L-lysine. The adipose tissue was cut into 
sections of 12-15 µm with a rotary microtome and dried at 37oC. After being fixed in 4% 
paraformaldehyde for 1 minute, the section was stained using Mayer’s hematoxylin for 5 
minutes, and rinsed in the tap water following dehydration in a series of alcohols from 
70%, 80%, 90%, and 95% to 100%. The slide was immersed in xylene for 3 minutes. The 
section was then mounted in xylene-based medium and observed under a light 
microscope. 
2.5.2. Immunohistochemistry 
The frozen subcutaneous adipose tissue was cut into 40 µm sections using a rotary 
microtome at -20ºC and then dried overnight at 37ºC. The sections were washed three 
times for 5 minutes each with PBS (pH 7.4) (table 2.5.1), then incubated in 3% hydrogen 
peroxide for 10 minutes to inactivate endogenous peroxidases. After washed three times 
using PBS for 5 minutes each, the sections were blocked by 5% rabbit serum for 10 
minutes. Anti-collagen VI antibody (goat IgG) (diluted 1:500) was added to each section 
after removing the blocking serum. The sections were incubated overnight at 4°C. The 
sections were washed three times with PBS for 5 minutes each. Peroxidase-conjugated 
rabbit antigoat IgG (diluted 1:200) was added and incubated with sections for one hour. 
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After washing three times with PBS, DAB (3, 3’- Diaminobenzidine) peroxidase 
substrate solution was added to the sections. A brown color indicating the presence of the 
target epitope appeared within 5 minutes. The reaction was stopped by immersing the 
slides in tap water. Sections were dehydrated following sequential ethanol and xylene 
treatment. The procedure was initiated with a 3 minute wash with 70% ethanol, followed 
by 90%, 95%, 100% ethanol and finally with a xylene wash done twice. The slides were 
mounted with cover slips and were examined under a light microscope.  
Table 2.5.1 Preparation of PBS for immunohistochemistry (Phosphate Buffered 
Saline, pH 7.4) 
Chemical compound Final concentration Amount in 1L 
NaCl   137.0 mM 8.0000 g/l 
KCl 2.7 mM 0.2013 g/l 
Na2HPO4 8.1 mM 1.1499 g/l 
KH2PO4 1.5 mM 0.2041 g/l 
 
2.6 Determination of triglyceride and glucose 
2.6.1 Enzymatic assay for triglyceride in plasma 
Triglycerides measurement involves enzymatic hydrolysis of triglycerides to 
glycerol and free fatty acids. The glycerol produced is then assessed following enzyme 
reactions by glycerol kinase (GK), glycerol -1- phosphate dehydrogenase (G-1-PDH) and 
diaphorase as indicated below: 
                          Lipoprotein lipase 
Triglycerides   Glycerol + Fatty acids 
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                                      GK                          
Glycerol + ATP G-1-P + ADP 
 
                                  G-1-PDH 
G-1-P + NAD  DAP + NADH 
 
                               Diaphorase 
NADH + INT   Formazan + NAD 
 
Glycerol is then phosphorylated utilizing ATP to form glycerol-1-phosphate (G-1-
P) and ADP. The G-1-P is oxidized to DAP coupled with the reduction of NAD to 
NADH in the reaction catalyzed by G-1-P dehydrogenase (G-1-PDH). Finally, 
diaphorase catalyzes the reduction of 2-(p-iodophenyl)-3-p-nitrophenyl-5-
phenyltetrazolium chloride (INT) to INTH (formazan) in the presence of NADH. 
Formazan, a coloured product, has an absorbance maximum at 500 nm. The intensity of 
the OD500 (optical density) is directly proportional to the triglyceride concentration of the 
samples. A liner standard curve was achieved (figure 2.6.1). The calculation of 
triglycerides concentration is shown as follows: 
calibrator ofionconcentrat
AA
AA
blankcalibrator
blanktest ×−
−=des(mg/dl)Triglyceri  
Example: 
ABLANK                 = 0.054 
ATEST                      = 0.676 
ACALIBRATOR      = 0.442 
401*250
054.0442.0
054.0676.0) =×−
−=des(mg/dlTriglyceri  
* Equivalent triglycerides concentration (mg/dL) of calibrator.  
Blood samples were collected as described in “section 2.4.1”. 
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Figure 2.6.1 standard curve of triglyceride  
 
2.6.2 Assay of blood glucose level 
The levels of glucose in whole blood were assessed using ONETOUCH® Ultra 
test strips provide by Lifescan Company. The method is used as a home device for 
diabetic patients. It is a simple, quick, sensitive and accurate method with less pain, and 
needs less blood samples. The test principle is based on an enzymatic procedure and 
electrochemical measurement where  
                                          glucose oxidase 
glucose + O2 + H2O                                       gluconate + H2O2   
A drop of blood (5 µl) is applied to the test strip. The glucose oxidase catalyzes the 
oxidation of the blood glucose to produce gluconate. During the reaction, electrons are 
transferred by an electrochemical mediator to the electrode surface. A small electrical 
current is produced and measured by the detector. The changes of the strength of the 
current represent the amount of glucose in blood.  
Blood glucose levels were assessed after 12 hours fasting. Before collecting the 
blood sample, the test strip was inserted into the test port of the meter. The test strip then 
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touched and held the blood, where the blood met the narrow channel on the strip. The 
blood drop was held until the blood had completely filled the window before the meter 
began to count down. The blood glucose levels would appear on the display of the meter 
in 5 seconds.  
                                               
 
 
 
 
 
 
 
    
    
Top Edge: apply a 
drop of blood here 
Confirmation Window: 
confirm enough blood has 
been applied to the Top 
Edge 
    
Fi
 
2.7
EL
co
an
 Contact Bar: insert 
this end of the test 
strip into meter. 
Push it in firmly 
until it will go no 
further.                                     
                                     (A)                                                            (B) 
                                              
gure 2.6.2 (A) ONETOUCH® Ultra test strip. (B) ONETOUCH® Ultra meter. 
 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA is a very sensitive method for quantitation assessment of specific proteins. 
ISA was employed for the estimation of insulin, leptin and TNFα. The optimal 
nditions for ELISA were determined by the grid method. It is a method to test many 
tibody pair concentrations using only one plate (table 2.7.1). 
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For leptin standard curve, for example, high affinity 96 well microtitre plates 
(Maxisorb, Nunc) were coated with 100 µl/well phosphate buffered saline (PBS) (table 
2.7.2) (pH7.4) containing 2 µg/ml goat anti-leptin IgG, and incubated overnight at room 
temperature. The plates were washed four times with PBS containing 0.05% Tween 20 
(PBS-T) and then blocked for at least one hour at room temperature with 300 µl/well PBS 
containing 1% bovine serum albumin (BSA), 5% sucrose and 0.05% NaN3. After four 
washes as above, 100 µl/ well standard leptin (62.5 pg/ml to 4 ng/ml), diluted in PBS-T 
containing 0.1% BSA (PBS-TB), or blood sample, was added into the plate and incubated 
at least 2 hours at room temperature. After washing the plate, 100 µl/well biotinylated 
goat anti-leptin IgG containing 100 ng/ml in PBS-TB was added to the plate and 
incubated for 2 hours at room temperature. Thereafter, 100 µl of extravidin-horse radish 
peroxidase, diluted in 1: 1000 in PBS-TB, was added per well to wash plates for 30 
minutes. After washing, immunoreactivity was detected by adding 200 µl/well 
tetramethylbenzidine dihydrochloride (TMB) as peroxidase substrate for 30 minutes at 
room temperature. The reactions were stopped by the addition of 50 µl/well 1M H2SO4.  
The OD was determined at 450 nm by using a plate spectrophotometric plate reader and 
data were analysed by Softmax®pro software. Dose response standard curve of leptin 
between 62.5pg/ml and 4 ng/ml were obtained. Results were quite comparable from other 
labs (Hardie et al., 1996). The other standard curves, using recombinant insulin and 
TNFα, were conducted for each ELISA assay. Insulin, leptin and TNFα levels in blood 
samples were assessed from the standard curve on each plate utilizing a linear fit of data.  
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Table: 2.7.1 An example of grid experiment for leptin detection antibody  
                      detection   assay 
50 ng/ml 
detection 
50 ng/ml 
detection 
100 ng/ml 
detection 
100 ng/ml 
detection 
200 ng/ml 
detection 
200 ng/ml 
detection 
No leptin No leptin No leptin No leptin No leptin No leptin 
4 ng/ml 
leptin 
standard 
4 ng/ml 
leptin 
standard 
4 ng/ml 
leptin 
standard 
4 ng/ml 
leptin 
standard 
4 ng/ml 
leptin 
standard 
4 ng/ml 
leptin 
standard 
 
Table 2.7.2. Preparation of PBS for ELISA (Phosphate Buffered Saline, pH 7.4) 
Chemical compound Final concentration Amount in 1L 
KCl 2.7 mM 0.20 g 
KH2PO4 1.5 mM 0.20 g 
NaCl 137.0 mM 8.00 g 
Na2HPO4•7H2O 8.06 mM 2.16 g 
 
 
2.8 Adipocyte culture 
2.8.1 3T3-L1 cell culture as a model for effect of olanzapine on triglyceride  
3T3 –L1 cells are widely used for study of adipocyte differentiation due to their 
ability to differentiate into adipocytes, i.e. following treatment with agents including 
dexamethasone (Dex), isobutylmethylxanthine (IBMX) and insulin. In the present study, 
the 3T3-L1 cell line was used to exam the effect of olanzapine on triglyceride levels in 
vitro. 
3T3-L1 cells, stored in liquid nitrogen, were thawed at 37°C, and then centrifuged 
at 1,200 rpm for 5 minutes. After discarding the supernatant, the cells were suspended by 
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1 ml preadipocyte culture medium containing 10% NBCS (table 2.8.1), and then 
transferred to 75 cm2 flask with 20 ml medium for culture. These cells were maintained 
in an incubator at 37°C, 5% CO2 for 3 days. Then the cells were washed with 0.9% saline 
solution and treated with 0.05% trypsin/0.02% EDTA solution for 30 seconds. After 
discarding the trypsin/EDTA solution, the cells were suspended with subculture medium 
containing 10% FBS. 5X105 cells were then seeded in to the 24-well plate. 
  After confluence in 2 days, the medium was replaced by differentiation medium 
containing 10% FBS, insulin (2.5 µg/ml), Dex (0.25 µM) and IBMX (200 µM) (table 
2.8.2). The cells were differentiated for 2 days. After differentiation, the cells were 
incubated in the maintaining medium containing 10% FBS and 2.5 µg/ml insulin for 
further study.   
2.8.2 MTT test 
MTT test is used to assay proliferation and viability of culture cells. As a 
tetrazolium salt, MTT can be cleaved to formazan by the "succinate-tetrazolium 
reductase" system, in part by the action of dehydrogenase enzymes, to generate reducing 
equivalents such as NADH and NADPH. This system belongs to the respiratory chain of 
the mitochondria and is only active in metabolically intact cells. 
Olanzapine at different concentrations, i.e. 1X10-6M, 1X10-5M, 1X10-4M, was 
added to medium. After 7-day’s treatment in a 24-well plate, 200 µl MTT solution was 
added to each well and incubated at 37°C for 4 hours. Then 400 µl acid-isoproponal 
(solvent) was added to each well and mixed thoroughly to dissolve the purple crystals. 
The plate was incubated overnight at 37°C. 100 µl solution was transferred to each well 
of a 96-well plate. The plate was read at 570 nm. 
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 2.8.3 Determination of cellular triglyceride levels in 3T3-L1 cells   
 3T3-L1 cells were treated with olanzapine at different concentrations, i.e. 1x10-5 
M, 5x10-5 M, and 1x10-4 M. After 6-day’s treatment, the medium was discarded. The 
cells were suspended in PBS after washed by cold PBS. The cells were then sonicated. 
The cellular triglyceride levels were detected by the method described in section 2.6.1.    
Table 2.8.1 3T3-L1 preadipocytes culture medium base (1 L) 
Chemical compound Amount in 1 L 
DMEM 10 g 
NBCS or FBS 100 ml 
D-glucose 3.5 g  
HEPES 3.9 g 
Sodium bicarbonate 1.5 g 
Sodium pyruvate 0.11 g 
The pH of the solution is adjusted with HCl to pH 7.2. The solution is filtered with 0.2 
µm filter.  
Table 2.8.2 3T3-L1 differentiation medium (100 ml) 
Chemical compound Amount in 100 ml 
DMEM base 88.2 ml 
FBS 10 ml 
Penicillin (100 U/ml) / Streptomycin (100 
µg/ml) 
1 ml 
Insulin (500 µg/ml) 1.0 ml 
IBMX  (0.1 M) 0.2 ml 
Dex (0.25 mM) 0.1 ml 
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2.9 Assessment of protein profile in adipose tissue 
2.9.1 Protein extraction and determinations 
The frozen adipose tissue was immersed in 50 mM Tris-HCl buffer (pH 7.4) 
containing 1 M NaCl and protease inhibitor (aprotinin 10 µg/ml, leupeptin 10 µg/ml, 
pepstatin A 1 µg/ml, PMSF 10 µM), and then homogenized by using a polytron 
homogenizer. After centrifugation at 15,000 g, 4 °C for 10 minutes, the supernatant was 
collected for protein assay. 
Protein concentration was determined by the Bradford method using Bio-Rad 
protein assay kit. A series of concentrations of Bovine serum albumin at 0, 0.016, 0.031, 
0.062, 0.125, 0.25, 0.5 mg/ml, were used as standards. The absorbance of the solution 
was read at 595 nm using spectrophotometric plate reader and data were analysed by 
Softmax®pro software. A linear BSA standard curve was constructed, from which the 
protein concentration of the test sample could be determined. 
2.9.2 Assessment of protein profile 
Equal amounts of total protein were electrophoresed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (15%). After electrophoresis, the 
protein profile on the gel was stained by a silver stain kit. A chromatic figure was 
obtained due to a redox reaction to reduce ionic silver to metallic silver occurred during 
the staining procedure. This method is 100 times more sensitive than Coomassie Blue and 
can detect protein at 0.1-1.0 ng levels. 
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2.10 Statistical analysis 
Analysis of weekly weight gain, food and water intake by two-way analysis of 
variance (ANOVA) was performed using STAT program. Blood levels of glucose, 
triglyceride, insulin, leptin and TNF-α were analysed by one-way ANOVA using SPSS 
program. Individual comparisons between means were made using student’s t- test. 
Correlation analysis was performed by Pearson’s method using SPSS program.  
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2.11 Research outline 
 
 
 
 
 
       Animal model
weight adipose tissue blood feeding 
Histochemical stain Glucose/triglycerideFood / water intakeBody Weight  Immunohistochemical stain Insulin/leptin/TNFαAdipose tissue Protein profile analysis 
Cell model
MTT test Cellular triglyceride test
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 3     Results 
3.1 HPLC identification of olanzapine  
Since in some studies olanzapine tablets were used, the content of olanzapine was 
estimated by HPLC. Pure olanzapine base was used as a reference standard. In the HPLC 
analysis, the time required for a target compound to elute is called retention time. 
Retention time for olanzapine under experimental condition is 12.19 minutes. The 
qualitative estimation was based on the peak surface area (or height). Figure 3.1.1 shows 
the chromatogram of olanzapine standards, diluted as 0.03 mg/ml, and olanzapine 
solutions from tablets containing olanzapine at 10 mg or 15 mg. Figure 3.1.2 shows the 
chromatogram of stability of olanzapine storage solution at 1, 3 and 7 days, respectively. 
The retention time of olanzapine is consistent with that of the pure compound. The 
content of olanzapine is exactly as it indicates for the tablet. Stock solutions prepared 
from olanzapine tablets are completely accurate as the concentrations indicated in the 
text.  
     
 
 
 
 
 
 
 
 36
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Figure 3.1.1 HPLC chromatogram of Olanzapine. (A) pure olanzapine base (0.03 mg/ml). 
(B) olanzapine solution (0.03 mg/ml) ( prepared from tablet containing 10 mg/tablet). (C) 
olanzapine solution (0.03 mg/ml) (prepared from tablet containing 15 mg/tablet). Volume 
for injection = 50 µl.  
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                 (A)                                        (B)                                                         (C) 
 
 
 
Figure 3.1.2 HPLC chromatogram of stability of olanzapine. (A) olanzapine solution 
(0.03 mg/ml) (storage for 1 day). (B) olanzapine solution (0.03 mg/ml) (storage for 3 
days). (C) olanzapine solution (0.03 mg/ml) (storage for 7 days).  Volume for injection = 
50 µl. 
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3.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
The optimum leptin antibody concentration is determined by grid experiment. The 
result displayed in figure 3.2.1 shows that the optimal range of concentrations for 
detection of leptin is anti-leptin goat IgG at 2 ng/ml and biotinylated anti-leptin goat IgG 
at 100ng/ml. The ELISA performed under these conditions are capable of detecting 
pictogram levels of leptin with low background (OD < 0.2).  
The standard curve obtained for leptin, insulin by ELISA is linear fit (Figure 
3.2.2). Knowing the absorbance of the sample assayed and the equation for the line of the 
standard curve, the concentration of cytokines in a sample is calculated as follows:  
y = ax + b 
x = (y-b) ÷ a 
where: y = absorbance of sample at 450 nm 
            x = sample cytokine concentration (ng/ml) 
            a = slope of standard curve 
            b = y – intercept of standard curve  
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Figure 3.2.1 Optimizing leptin antibody concentrations by grid experiment.   
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Figure 3.2.2 Standard curve of leptin, insulin and TNFα by ELISA 
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3.3 Effects of olanzapine on cumulative body weight gain  
As can be seen in figure 3.3.1, olanzapine induced significant increases in 
cumulative weight gain in female rats over the 4-week treatment period relative to control 
group (p<0.05). In week 1 and 2, a rapid growth was seen in the group treated with 
olanzapine at 0.03 mg/ml drinking water. Cumulative body weight gain remained 
constant over the duration of the test period. A dose–related increase in cumulative body 
weight gain was observed. The group treated with 0.03 mg/ml experienced marked 
weight gain just after 1-week treatment and was constant for four weeks. However, the 
group treated with lower concentration of olanzapine (0.01 mg/ml) began to gain weight 
significantly only after the second week of treatment.  
In the subsequent experiment, different concentrations of olanzapine (0.02 - 0.04 
mg/ml) were used. Twice/per week fasting and weekly blood collection were conducted. 
Olanzapine did not yield a significant effect on weight gain. It seems that olanzapine 
failed to produce weight gain and this might be due to these relatively invasive treatments 
(fasting and venous blood collection) (Figure 3.3.2). 
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Figure3.3.1. Chronic effects of olanzapine administered via drinking water (0.01 - 0.03 
mg/ml) on cumulative body weight gain in Wistar female rats. Values represent mean ± 
S.D.; n = 5 per group (* p ≤ 0.05).   
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Figure3.3.2. Chronic effects of olanzapine administered via drinking water (0.02 - 0.04 
mg/ml) on cumulative weight gain in Wistar female rats. Animals were subjected to 
repeated harsh treatment (i.e. fasting and collection of venous blood. Values represent 
mean ± S.D.; n = 5 per group 
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3.4 Effect of olanzapine on the weight of adipose tissues 
The chronic effect of olanzapine on the total mass of subcutaneous and abdominal 
adipose tissue in female Wistar rats was also assessed. A significant increase in both 
tissues was detected in animals treated with olanzapine (0.006 mg/ml and 0.01 mg/ml) 
(Figure 3.4.1). A large within-group variance was also observed in olanzapine-treated 
group, especially in the group treated with dose of 0.03 mg/ml, which renders the 
increase of fat tissue masses not significant. 
Correlation analyses were performed on the weight gain vs. the masses of adipose 
tissue. The results revealed that there was a significant positive correlation between 
weight gain and the weight of adipose tissue from two distinct regions (p < 0.01) (Figure 
3.4.2). 
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Figure 3.4.1 Effect of olanzapine administered via drinking water (0.003-0.03 mg/ml) on 
the mass of (A) abdominal adipose tissues, and (B) subcutaneous adipose tissue in Wistar 
female rats after 4-week treatment. Values represent mean ± S.D.; n = 5 per group (* p ≤ 
0.05) 
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Figure 3.4.2 Scattergram of the relationship between weight gain and total mass of (A) 
abdominal adipose tissue, and (B) subcutaneous adipose tissue of rats after four-week 
olanzapine-treatment. 
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3.5 Effect of Olanzapine on food intake and water intake 
The effect of olanzapine on food and water intake was also measured, as shown in 
figure 3.5.1. Olanzapine induced a significant increase in food intake, but this was 
observed only after one-week treatment. During the following 4-week study olanzapine 
did not significantly affect food intake. 
The effect of olanzapine on water intake is shown in figure 3.5.2. The drug 
appeared to increase water consumption after one-week treatment and maintained its 
effect up to third week. However, significant increases were not obtained at all time 
points or concentrations of olanzapine.  Olanzapine at 0.006 mg/ml induced a marked 
increase in water consumption in week 3 (p < 0.05), and at 0.01 mg/ml increased water 
intake significantly in week 1 (p < 0.05). No effect of olanzapine at 0.003 mg/ml and 0.03 
mg/ml were observed on water intake in female rats compared to the control group. The 
large individual variation makes it difficult to find any significant effect.  
The following analysis is to determine whether food intake was directly related to 
weight gain. In this analysis, all treated animals were pooled and divided into high and 
low weight gain group based on the mean value of their weight gain (54.5 g), without 
considering the concentration of olanzapine. Olanzapine significantly increased food 
consumption in rats with high weight gain also only in week 1 (p < 0.05) (Figure 3.5.3). 
This effect disappeared after two-week treatment. However, olanzapine did appear to 
increase feed efficiency in drug-treated rats with high weight gain. Feed efficiency is 
defined as weight gain (g)/food intake (g). Interestingly, a significant lower feed 
efficiency was observed in low weight gain group in week 1, 2 and 4 (p < 0.05) (Figure 
3.5.4). 
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Figure 3.5.1 Effect of olanzapine administered via drinking water (0.003-0.03 mg/ml) on 
food intake in Wistar female rats. Values represent mean ± S.D.; n = 5 per group (* p ≤ 
0.05) 
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Figure 3.5.2 Effect of olanzapine administered via drinking water (0.003-0.03 mg/ml) on 
water intake in Wistar female rats. Values represent mean ± S.D.; n = 5 per group (* p ≤ 
0.05) 
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Figure 3.5.3 Effect of olanzapine administered via drinking water (0.003 mg/ml to 
0.03mg/ml) for 4 weeks on food intake in relationship to weight gain in Wistar female 
rats. Olanzapine-treated animals were regrouped based on difference of weight gain (Low 
weight gain < 54.5g, high weight gain > 54.5g).  Values represent mean ± S.D.; n = 5; 11; 
9 (* p ≤ 0.05) 
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Figure 3.5.4 Effect of olanzapine on feed efficiency in relationship to weight gain in 
Wistar female rats. Olanzapine-treated animals were regrouped based on difference of 
weight gain (Low weight gain < 54.5g, high weight gain > 54.5g).  Values represent 
mean±S.D.; N = 5; 11; 9 (* p ≤ 0.05) 
 
 
 
 
 
Fe
ed
 e
ffi
ci
(g
 W
t g
ai
n/
g 
Fo
od
)
en
cy
 
control
olanzapine-1 (with low
weight gain)
olanzapine-2 (with high
weight gain)
*
*
*
*
 52
3.6 Effect of olanzapine on blood glucose and plasma triglyceride levels 
Blood glucose levels are increased in olanzapine-treated animals. As can be seen 
in figure 3.6.1- (A), a significant increase in glucose levels was detected in rats treated 
with 0.01 mg/ml of olanzapine during week 3, and in rats treated with 0.03 mg/ml during 
week 2 and 3. A follow-up experiment shows that glucose levels in animals treated with 
different concentrations of olanzapine were not different from that of control animals in 
week 4 (Figure 3.6.1-(B)). 
Plasma triglyceride levels were unchanged in these rats following olanzapine 
treatment for 4 weeks (Figure 3.6.2). 
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Figure 3.6.1 Effect of olanzapine on blood glucose levels in Wistar female rats. 
Olanzapine was administered via drinking water after 4 weeks. Values represent mean ± 
S.D.; n = 5 per group (* p ≤ 0.05) 
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Figure 3.6.2 Effect of olanzapine on plasma triglyceride levels in Wistar female rats. 
Olanzapine was administered via drinking water for 4 weeks. Values represent mean ± 
S.D.; n = 5 per group. 
 
 
 
 55
3.7 Effect of olanzapine on viability and triglyceride content in cultured adipocytes 
In order to assess whether olanzapine directly affect triglyceride level in 
adipocytes, an adipocyte cell culture, 3T3-L1cell line were employed. In vivo, olanzapine 
is extensively distributed throughout the body.  93% of olanzapine would be bound to 
plasma proteins over the concentration range of 7 to 1100 ng/ml. Based on the plasma 
concentrations, concentrations of olanzapine, 1×10-6 M to 1×10-4 M, were used in the 
present cell experiment. 
At the concentrations of 1×10-6 M to 1×10-4 M, Olanzapine does not seem to 
affect the viability of 3T3-L1 adipocytes in vitro after 7-day’s treatment (figure 3.7.1).  
Neither does it alter the cellular triglyceride levels of differentiated 3T3-L1 adipocytes 
after 6-day’s treatment (figure 3.7.2).   
 
 56
         
 
 
 
 
1.700
1.800
1.900
2.000
2.100
2.200
O
D
 5
70
nm
no OLAN
1X10-6 M
1X10-5 M
1X10-4 M
no-olan 1X10-6M 1X10-5M 1X10-4M
concentration (M)
 
 
 
 
 
 
 
 
 
 
Figure 3.7.1 Effect of olanzapine on viability of 7-day’s treated differentiated 3T3-L1 
adipocytes by MTT test. Values represent mean±S.D. n = 4 wells per group. 
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Figure 3.7.2 Effect of olanzapine on cellular triglyceride levels of 6-day’s treated 
differentiated 3T3-L1 adipocytes. Values represent mean±S.D. n = 4 wells per group. 
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3.8 Effect of Olanzapine on plasma levels of leptin, insulin and TNFα 
In Wistar female rats, olanzapine administered via drinking water induced a 
significant increase in plasma insulin levels after four-week treatment (Figure 3.8.1). 
However, olanzapine did not significantly affect levels of plasma leptin and TNF-α after 
four-week treatment. A very large individual variance in these animals was observed 
(Figure 3.8.2).  
However, after regrouping the olanzapine-treated animals based on their weight 
gain at the end of the treatment, analysis revealed that plasma levels of insulin and leptin 
were significant correlated to the weight gain in the treated rats (p < 0.05, Figure 3.8.3).        
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Figure 3.8.1 Effect of olanzapine administered via drinking water (0.003-0.03 mg/ml) on 
plasma insulin levels in Wistar female rats after four weeks of treatment. Values 
represent mean ± S.D.; n = 5 per group (* p ≤ 0.05) 
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Figure 3.8.2 Effect of olanzapine administrated via drinking water (0.003-0.03 mg/ml) on 
plasma (A) leptin levels and (B) TNFα levels in Wistar female rats after four weeks of 
treatment. Values represent mean ± S.D.; n= 5 per group 
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Figure 3.8.3 Effect of olanzapine on plasma levels of (A) insulin and (B) leptin in Wistar 
female rats. Olanzapine-treated animals were divided to two groups (Low weight gain < 
54.5g, high weight gain > 54.5g).  Values represent mean ± S.D.; n = 5; 11; 9 (* p ≤ 0.05) 
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3.9 Correlation between plasma levels of insulin, leptin, weight gain and weight of 
adipose tissues 
In order to reveal how plasma insulin and leptin are related to olanzapine-induced 
weight gain, correlation analyses were performed between the levels of insulin, leptin and 
weight gain after four weeks of treatment. The scatter gram is shown in figure 3.9.1 (A). 
The correlation (R = 0.116) observed between insulin levels and weight gain was not 
statistically significant (p = 0.58). However, a positive correlation was found between 
leptin level and weight gain (R= + 0.537, p=0.006) (Figure 3.9.1(B)). 
Correlation analyses were also performed on the levels of insulin and leptin vs. 
the masses varies adipose tissues. Once again no correlation was found between insulin 
levels and the mass of subcutaneous and abdominal adipose tissue (p=0.487 and 0.375, 
respectively) (Figure 3.9.2). A marked positive correlation was observed between leptin 
levels and both adipose tissues (p = 0.006 and 0.003, respectively) (Figure 3.9.3).   
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Figure 3.9.1 Scattergram of correlation between weight gain and plasma level of insulin 
and leptin in rats after four-week olanzapine treatment.  
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Figure 3.9.2 Scattergram of correlation between total masses of various adipose tissues 
and plasma levels of insulin of rats after four-week olanzapine treatment. 
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Figure 3.9.3 Scattergram of correlation between total masses of adipose tissues and 
plasma levels of leptin of rats after four-week olanzapine treatment. 
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3.10 Olanzapine alters some morphological appearance of subcutanous adipose   
         tissue 
 A consistent effect of olanzapine observed in this study was the dramatic 
morphological changes in the subcutanous adipose tissue. The adipose tissues from 
control animals were white, bright with puffy appearance. In contrast, the olanzapine-
treated adipose tissues were yellowish to brownish, non-transparent with “fish egg-like” 
granule appearance (Figure 3.10.1). Apparent enlarged vessels in the adipose tissues of 
the olanzapine-treated animals were also observed. 
            Since quantification method for the morphological changes in fat adipose tissue is 
not available, the degree of changes were visually assessed and independently confirmed 
by other colleagues. 
After 8-week treatment with olanzapine at concentration of 0.02 mg/ml and 0.04 
mg/ml, the morphological change in subcutaneous adipose tissue was observed in all the 
treated animals (Table 3.10.1, 3.10.2). The changes were semi-quantified from “-” 
(representing white colour or puffy appearance) to “+” (sparsely or faint colorization and 
fish-egg appearance), “++” (intermediate of colorization and fish-egg appearance) to 
“++” (representing yellow colour or fish-egg appearance).     
It is interesting to note that these morphological changes were not generally 
applied to all adipose tissues. Indeed, no morphological changes in abdominal adipose 
tissues in the same olanzapine-treated rats were observed.  
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Figure 3.10.1 Effect of chronic treatment of olanzapine on morphological changes of 
subcutanous adipose tissues in Wistar female rats (A) gross morphological change; (B) 
magnification: 2X. 
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Table 3.10.1  Effect of olanzapine on the colour of subcutanous adipose tissues in 
Wistar female rats.  Rats were treated with vehicle or olanzapine for 8 weeks. n = 5 
per group. (white : -, yellow: +).  
Group (n=5) 
No.  
Control   Olanzapine-1 
(0.02 mg/ml) 
Olanzapine-2 
(0.04 mg/ml) 
            1               –            +/++              ++ 
            2               –             +             +/++ 
            3               –             +              +++ 
            4               –           +/++               ++ 
            5               −            ++               ++ 
 
 
 
Table 3.10.2  Effect of olanzapine on the texture of subcutanous adipose tissues in 
Wistar female rats.  Rats were treated with vehicle or olanzapine for 8 weeks. n = 5 
per group. (puffy-appearance: -, fish egg-appearance: +). 
Group (n=5) 
No. 
Control  Olanzapine-1 
(0.02 mg/ml) 
Olanzapine-2 
(0.04 mg/ml) 
            1              –            +/++              ++ 
            2              –             ++              ++ 
            3              –              +             +++ 
            4              –             ++              ++ 
            5              –             ++              ++ 
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3.11 Histochemical examination of the adipose tissues  
The histological examination using hematoxylin stain revealed the difference 
between adipose tissues obtained from control and olanzapine treated animals with 
olanzapine. As can be seen in figure 3.11.1, more nuclei and extracellular matrix 
structure were observed surrounding the adipocytes in olanzapine-treated animals. 
It is known that hematoxylin is capable of staining collagen. Therefore, a specific 
immunohistochemical stain of collagen VI was employed to examine the adipose 
collagen. A strong positive stain was observed in olanzapine-treated adipocyte (Figure 
3.11.2). It is clear that the collagen VI protein was increased in the extracellular matrix 
adipose tissues from olanzapine-treated rats.     
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Figure 3.11.1 Histochemical examination of subcutanous adipose tissues in control and 4-
week olanzapine-treated (0.03 mg/ml) Wistar female rats (↑: nucleus, ►: extracellular 
matrix). (A) hematoxylin-stained normal adipocytes from control animals; (B) 
hematoxylin-stained adipocytes from olanzapine-treated animals. Original magnification: 
100X; scale bar:100 µm. 
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Figure 3.11.2 Effect of olanzapine (0.03 mg/ml) via drinking water after 4-week 
treatment on adipocyte collagen VI in Wistar female rats. Adipocyte was 
immunohistochemical stained by collagen VI (arrowheads). (A) adipocyte from control 
animal; (B) adipocyte from olanzapine-treated animals. Original magnification: 100X; 
scale bar: 100 µm. 
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3.12 Effect of olanzapine on protein profile of adipose tissue  
Silver stain reveals that the protein profile of adipose tissue following olanzapine 
treatment altered in comparison to the protein profile of the control adipose tissue (figure 
3.12.1). At least three protein expressions, i.e. molecular weight approximately 15 KDa, 
27 KDa, 30 KDa, respectively, were found increased in olanzapine-treated adipose tissue 
and two proteins expressions, approximately 21 KDa and 46 KDa, were decreased. 
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Figure 3.12.1 Effect of olanzapine on protein profile of adipose tissue after 4-week 
treatment via drinking water. (1) ⎯ (3): protein profile from control adipose tissues; (4) 
⎯ (6): protein profile from olanzapine-treated (0.03 mg/ml) adipose tissues. 
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4  Discussion  
 
4.1 Effect of olanzapine on body weight 
In order to investigate the mechanism of olanzapine-induced weight gain, an 
animal model is required. We adopted a method by administering olanzapine to female 
Wistar rats via drinking water (Leander et al., 2001). The body weight gain was rapidly 
induced in the first and/or second week (Figure 3.3.1, Figure 3.3.3). Olanzapine 
administration at 0.03 mg/ml significantly increased body weight after 1 week of 
treatment and this increase persisted for 4 weeks (Figure 3.3.1). Although olanzapine 
readily induces weight gain in humans, its effect in rodents appeared less prominent. 
Clinical pharmacology studies show that olanzapine has high affinity binding to 
the following receptors: serotonin 5HT2A/2C (Ki = 4 and 11 nM, respectively), dopamine 
D1-4 (Ki = 11-31 nM), muscarinic M1-5 (Ki = 1.9-25 nM), histamine H1 (Ki = 7 nM), and 
adrenergic α1 receptors (Ki = 19 nM). Olanzapine binds weakly to GABA-A, BZD, and β 
adrenergic receptors (Ki > 10 mM). Daily dose recommended in clinical treatment is 
between 5 mg/day to 20 mg/day, roughly 0.1 mg/kg to 0.4 mg/kg per day. The doses of 
olanzapine used in the present animal study for rats are between 0.3 mg/kg to 6 mg/kg. 
These doses are reasonably close to the clinical dosage.  
It has been reported that female Sprague Dawley rats treated with olanzapine via 
drinking water gained weight (Leander et al., 2001). Other studies have also described 
effects of olanzapine on weight gain in rats using different drug administration routes. 
Goudie and colleagues showed that female Wistar rats receiving daily twice injections of 
olanzapine at a concentration of 4.0 mg/kg exhibited body weight gain after 2 days, and 
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up to 10 days of treatment (Goudie et al., 2002). Both Arjona and colleagues, Pouzet and 
colleagues also showed that female Sprague Dawley rats or female Wistar rats showed 
marked weight gain following olanzapine treatment via gavage at 1.2 mg/kg, or at 5.0 
and 20 mg/kg (Arjona et al., 2004; Pouzet et al., 2003). Fell and colleagues also found 
that olanzapine induced significant increase in body weight among female Lister rats 
treated with doses of 1.0 and 4.0 mg/kg via intraperitoneal route (i.p.) (Fell et al., 2004). 
In contrast to these injection methods, administration of olanzapine via drinking water is 
less invasive and olanzapine is orally administered in humans. 
In the present study, olanzapine is capable of increasing weight gain in female 
Wistar rats. The effect of olanzapine on CD-1 female mice was also tested (unshowed 
observation). The drug at similar concentration as 0.01 and 0.03 mg/ml via drinking 
water, or at dose as 3 mg/kg via gavage, failed to influence weight gain. Moreover, the 
results from other studies indicated that male rats did not exhibit antipsychotic-induced 
weight gain (Pouzet et al., 2003). The possible reason might be that physiological period 
and physical activity are different between male and female rats. But the exact 
mechanism is still unclear. Therefore, differences in species and gender may affect the 
outcome of olanzapine’s effect. 
Results also indicate that a successful drug effect on weight gain was not only 
related to dose, but also related to how animals were handled. When rats were treated 
with low dose, i.e. olanzapine solution of 0.003 mg/ml, a significant weight gain cannot 
be obtained. The effect is therefore dose-dependent. Study of Fell and colleagues showed 
that olanzapine at a low dose, e.g. 0.5 mg/kg, did not induce weight gain in female Lister 
rats (Fell et al., 2004). In one experiment of the present investigation, the rats were 
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treated at 0.02 mg/ml or 0.04 mg/ml, approximately 2.4 mg/kg to 6 mg/kg, and 
significant body weight gain was not obtained. Neither food nor water intake were 
increased (data not shown). This was probably due that the applied stressful treatment 
was too stressful to the animals.  During the drug treatment period, the animals were 
fasted twice a week, 12 hours each time, and blood samples were collected each week. 
Animals had to be immobilized for at least 15 minutes during the blood collection. This 
excessive treatment might have been overly stressful to these animals. It is indicated that 
severe and prolonged stress impairs normal physiology and nullified the olanzapine-
induced weight gain. Therefore, in the study on effect of olanzapine on weight gain, any 
stressful treatment to the animals should be avoided. 
The rats also showed marked individual difference in weight gain. In the dose 
dependent experiments, a large within-group variance was always observed which 
diminished the power of analysis of effect of olanzapine on weight gain in the whole 
group.  After analysis of the distribution of the weight gain in the treated rats, in a 
concentration range (0.003 mg/ml ⎯ 0.03 mg/ml), it was determined that 9/20 (45%) of 
the animals gained more weight. After 1-week treatment, the increase was evident and 
persisted during the period of treatment. The remainder, e.g. 11/20 (55%) rats, obtained 
had no or only moderate weight gain.  Clinical reports have shown that only a portion, 
about 30% of olanzapine-treated patients gain weight (Green, 2000). Our animal data 
seem comparable to that of the clinical observations.  
A number of studies have shown that body fat increase is a determining factor of 
weight gain-associated mortality (Eder et al., 2001). In the present study, olanzapine fed 
via drinking water at 0.006 and 0.01 mg/ml significantly increased abdominal fat 
 76
deposition, and this effect was also observed in 0.03 mg/ml treated group. However, due 
to the large variance in this group, there was no difference compared to the control group. 
Other laboratories also observed a large variance in the olanzapine-treated female rats 
(Daniels et al., 2003; Fell et al., 2004). Clinical studies demonstrated that olanzapine-
induced weight gain in patients was accompanied with an increase in body fat (Eder et 
al., 2001; Murashita et al., 2005; Ryan et al., 2004). An analysis of visceral fat 
distribution pattern reveals that patients after olanzapine treatment had a higher level of 
intra-abdominal fat than that of control subjects. Interestingly, there was no significant 
difference in subcutaneous fat (Ryan et al., 2004). The present data indicated that 
olanzapine-induced body weight gain in rats was also attributable to an increase in both 
subcutaneous and intra-abnormal adipose tissues.  
Olanzapine significantly increased food and water intake during the test period. 
However, significant increase in food consumption was observed only in the first week. 
No consistent increase in food intake was observed during the whole period of treatment. 
Nevertheless, the finding of this study is consistent with a number of clinical observations 
and animal studies that olanzapine induces short-term hyperphagia in both patients and 
rodents. Two clinical studies indicated that although inconsistent with time course of 
treatment, increase in caloric intake was observed in treated patients, and there was no 
change in physical activity of these patients (Eder et al., 2001; Gothelf et al., 2002). In 
rodent studies, a short-term olanzapine-induced hyperphagia was observed by different 
groups, although this effect may vary with dose, methods of administration and 
measurement (Arjona et al., 2004; Fell et al., 2004; Hartfield et al., 2003; Kaur et al., 
2002; Lee et al., 2002; Pouzet et al., 2003; Thornton-Jones et al., 2002). Increase in 
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caloric intake without accompanied increase in physical activity would cause body 
weight gain. The enhancement on feed efficiency seen in the overweight rats in the 
present study may explain at least in part how drug-induced weight gain is related to 
increased food intake without marked behavior change. Increase in water intake in these 
treated rats is comparable to the study of Fell and colleagues (Fell et al., 2004). Serotonin 
is well recognized in the control of food intake (Arjona et al., 2004) and histamine is a 
well-known regulator of water intake (Casey et al., 2001; McIntyre et al., 2001a; 
McIntyre et al., 2001b). Olanzapine exhibits broad a pharmacological profile. The 
blockade of 5-HT2C and H1 receptors by olanzapine may be responsible for the change of 
feeding behavior.  
 
4.2 Effect of olanzapine on blood levels of glucose, triglyceride and cytokines 
In the present study, olanzapine exhibited some effects on the blood glucose level, 
but not on the triglyceride levels. These results are inconsistent to the clinical data. 
Different clinic reports showed that after 14 weeks to 25 months treatment with 
olanzapine, around 11% to 44% of patients were hyperglycemic (Melkersson et al., 2004; 
Newcomer, 2004; Wirshing et al., 2002), while around 39% to 62% of patients were 
hypertriglyceridemic (Casey, 2004; Melkersson et al., 2000; Melkersson et al., 2004; 
Wirshing et al., 2002). A retrospective analysis showed that the mean time to peak 
triglyceride levels in treated patients was 10.0 months (Casey, 2004). A similar result 
from other lab also showed that olanzapine did not induce hyperglycemia in male 
Sprague-Dawley rats (Patel et al., 2004). Therefore, the effect of olanzapine on blood 
glucose and triglyceride levels may be influenced by the period of treatment. The small 
 78
number of animals in the present series of experiments may also limit the power of 
analyses. It is possible that the apparent discrepancy may be due to species difference, 
insufficient treatment duration, and sample size. 
Only blood insulin levels, not leptin and TNF-α levels, were found to be 
significantly affected by olanzapine, but the effect was not dose-dependent. Both insulin 
and leptin levels were found positively correlated with high weight gain in the 
olanzapine-treated animals. Insulin, the most important hormone involved in regulating 
glucose metabolism, has been reported to be increased in olanzapine-treated patients even 
without an increase in glucose (Eder et al., 2001). Significant increase in incidence of 
pancreatitis, i.e. 33%, was found associated with olanzapine treatment (Newcomer, 
2004). A recent in vitro finding suggests that olanzapine may affect insulin release from 
pancreatic β cells (Melkersson, 2004). But to date, there is no evidence to show that an 
increase in insulin level is related to olanzapine’s effect on the pancreas. The present 
experiment did not show a significant correlation between weight gain and the blood 
insulin levels, nor between the increase in adipose masses and insulin. In contrast, the 
level of leptin was highly correlated with both body weight gain and adipose tissue 
masses. Since leptin is synthesized from adipocyte, in contrast to insulin which is 
secreted from pancreatic cells, such a correlation can be expected. A positive correlation 
between leptin and BMI was also reported (Atmaca et al., 2003). Higher rates of diabetes 
have been reported in olanzapine-treated patients and many olanzapine-treated patients 
have recovered from diabetes after discontinuing of the medication (Melkersson et al., 
2004). It is quite possible that an insulin and leptin resistance might be induced by 
olanzapine.  
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The role of TNFα in olanzapine-induced weight gain has drawn some attention 
but little is known. TNFα and its receptors are increased in clozapine–treated patients 
(Pollmacher et al., 1996). An increase in TNFα receptor levels was also found in 
olanzapine-treated patients (Schuld et al., 2000). Olanzapine is chemically very similar to 
clozapine. The circulatory TNFα receptor is thought to be a sensitive marker for TNFα 
activity. Many studies have shown that TNFα may induce insulin resistance, leading to 
impaired glucose metabolism (McIntyre et al., 2001a; Zimmermann et al., 2003). Both 
TNFα and its receptors can be synthesized by adipocytes. Blood TNFα was not 
correlated to body weight change in the present experiment. Results do not support the 
idea that olanzapine affect the involvement of TNFα. However, the large within-group 
variation makes any conclusion difficult. The methodology has some limitation. In order 
to reassess the role of TNFα in olanzapine-induced weight gain, improved ELISA or 
larger number of animals is required. TNFα receptor levels were not examined in the 
present study. Clearly, further study is needed in order to delineate the role of TNFα 
system in olanzapine-induced weight gain.   
 
4.3 Effect of olanzapine on adipocyte 
That olanzapine dramatically altered the morphology of adipose tissues was a 
serendipitous finding. The effect was consistent and reproducible in most olanzapine-
treated animals. This is the first observation that olanzapine not only increased the 
deposition of adipose tissue, but also changed the morphology of adipose tissue. Such 
morphological change was detected even in olanzapine-treated rats without obvious 
weight gain. It was thought that adipocytes differentiation might be influenced by 
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olanzapine. Due to the difficulties in identifying the structure of adipocyte at early 
development stage, marker proteins representing adipose differentiation was assessed. It 
has been found that morphology changes in adipocyte differentiation are accompanied 
with alterations in extracellular matrix components. As one component of extracellular 
matrix, the α chain 2 of type VI collagen is known to be an early marker for 
differentiation of adipocytes. Collagen VI levels are increased several-fold and persisted 
after initiation of adipose conversion (Klaus, 2001, Nakajima et al., 2002).  In the present 
study, the immunohistochemical stain revealed that indeed extracellular collagen VI 
expression of adipocytes was dramatically enhanced. The presence of such collagen VI 
change suggests that an enhancement of adipocyte differentiation was stimulated by 
olanzapine treatment. The increase in adipose tissue mass in obesity includes both 
hyperplasia and hypertrophy. The result of collagen stain indicates that olanzapine-
induced weight gain is probably in part due to the stimulation of adipocyte 
differentiation.   
It is interesting to note that although the increase of adipose tissue mass was seen 
in both abdominal and subcutaneous, such a morphological change was primarily 
constrained in subcutaneous fat deposition. The different effects of olanzapine on 
regional adipose tissues are unclear.  
The protein profiles in olanzapine-treated adipose tissues were also substantially 
altered. It has been shown that during the stage from adipoblasts to mature lipid-
containing adipocytes, a large set of enzymes and proteins emerge and are involved in the 
different developmental stages (Klaus, 2001). Several adipose proteins were found 
substantially changed both increase and decrease by olanzapine. These proteins have not 
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been identified. It remains to be established whether these proteins are involved in or a 
result of adipose differentiation. Nevertheless, the result indicates that dramatic change in 
metabolism in adipose take place following chronic treatment of olanzapine. 
 In the present in vitro experiment using cultured differentiated 3T3-L1 
adipocytes, olanzapine did not affect the viability and proliferation of the cells, as 
revealed by MTT test. Olanzapine also did not change the cellular triglyceride level in 
treated 3T3-L1 adipocytes. Upon growth arrest in the presence of fetal bovine serum and 
with the stimulation of dexamethasone (Dex), isobutylmethylxanthine (IBMX) and 
insulin, triglyceride starts to accumulate in 3T3-L1 cells and to form cytoplasmic lipid 
vesicles (Croissandeau et al., 2002). The lipid accumulation is an event which appears 
when the immature adipocyte differentiates to mature adipocyte (Klaus et al., 2001). The 
unchanged cellular triglyceride levels following olanzapine treatment indicated that 
olanzapine did not directly affect adipocytes differentiation in vitro. It is hypothesized 
that some endocrine factors, which altered by olanzapine, may mediate the effect of 
olanzapine on adipose tissue in vivo.             
The deposition of white adipose tissues is known to be dependent on gender. In 
humans, abdominal fat mass is predominant in the male, while subcutaneous fat mass is 
more prominent in the female (Klaus et al., 2001). Increased abdominal adipose tissue, 
especially visceral abdominal adiposity can increase insulin resistance and contribute to 
hyperglycemia and diabetes (Haupt et al., 2001). In the present study, treated subjects 
with morphological change in the subcutaneous part were all female rats. It is yet to be 
determined whether olanzapine exerts the same effect on adipose differentiation in male 
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rats or mice. It is also very interesting to know whether morphological changes of 
adipocytes would take place in patients treated with olanzapine. 
4.4 Conclusion 
In the present study, an animal model was employed to investigate the mechanism 
of olanzapine-induced weight gain. Insulin and leptin were found changed in association 
to olanzapine-induced weight gain. The morphological change and increase in fat 
deposition contributed towards the weight gain during olanzapine treatment. However, 
there are still many questions to be answered.  
Firstly, it would be very interesting to examine how olanzapine influences feeding 
behavior, which may be related to its pharmacological profile. The accurate feeding 
patterns should be monitored, including the frequency, duration time, and meal size. 
Meanwhile, the levels of neurotransmitters in the brain should be tested to determine 
which one is correlated to the change in feeding behavior. 
Secondly, although insulin and leptin appear to be involved in olanzapine-induced 
weight gain, the mechanism involved in olanzapine-induced hyperinsulinemia is still 
unknown. Since the prevalence of diabetes is significantly higher in olanzapine-treated 
patients, it is necessary to understand how olanzapine influences pancreas and the insulin 
signal pathway.  
Further research is required to determine the molecular mechanism of olanzapine-
stimulated adipocyte differentiation. It would be interesting to know how olanzapine acts 
on adipocytes and why olanzapine primarily acts on subcutaneous adipocytes. It is known 
that preadipocyte proliferation, differentiation and their interrelations are very complex. It 
would be interesting to know whether hormones, neural system, and paracrine factors are 
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involved, and how the effect is related to gender. An animal model for studying the 
olanzapine-induced weight gain will be useful in uncovering the underlying mechanism 
of weight gain induced by atypical antipsychotics. Clearly, it is important to answer that 
question whether the results from the animal studies can be translated to the clinical 
situation.  
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Appendix   List of chemicals and reagents  
 
Chemicals                                                                                                       Suppliers 
 
Acetic acid                                                                                                            BDH 
Acetonitrile                                                                                                           BDH 
ATP                                                                                                                      Sigma  
Bovine serum albumin(BSA)                                                                              Sigma 
Chloral hydrate                                                                                                    Sigma  
Diaphorase                                                                                                           Sigma  
DAB (3, 3’- Diaminobenzidine)                                                                          Sigma  
Dexamethasone (Dex)                                                                                         Sigma    
D-glucose                                                                                                             Sigma  
Disodium phosphate anhydrous                                                                           EMD  
DMEM                                                                                                                 Sigma 
EDTA                                                                                            Sigma  
Ethanol                                                                                         Chemical Alcohol Inc. 
Eosin                                                                                                  Ricca chemical Co. 
Extravidin-horse radish peroxidase                                                Sigma  
Fetal calf serum (FBS)                     Hyclone 
Glycerol kinase                                                                                Sigma  
Glycerol -1- phosphate dehydrogenase                                           Sigma  
HEPES                                                                                             Sigma  
Mayer’s Hematoxylin                                                                      Sigma  
Hydrogen peroxide                                                                          EMD  
Isobutylmethylxanthine (IBMX)                                                                           Sigma 
Lipoprotein lipase                                                                             Sigma  
New born calf serum (NBCS)                                                          Sigma  
Olanzapine                                                                                    Eli Lilly  
Paraformaldehyde                                                                            Sigma 
Penicillin                                                                                          Sigma  
Phosphoric acid                                                                                                      Fisher  
poly-L-lysine                                                                                                          Sigma                                    
2-(p-iodophenyl)-3-p-nitrophenyl-5-phenyltetrazolium chloride (INT)                Sigma  
Potassium chloride                                                                                                 EMD 
Potassium phosphate                  EMD 
Sodium azide                      Aldrich chemical  
Sodium bicarbonate                                                                                               EMD 
Sodium hydroxide                                                                                                  Sigma 
Sodium Phosphate Dibasic Anhydrous                                                                  EMD 
Sodium pyruvate                                                                                                    Sigma          
Streptomycin                                                                                                          Sigma 
Sulphuric acid                                                                                                         BDH 
Tetramethylbenzidine dihydrochloride (TMB)                                                      Sigma  
Triethylamine                                                                                                         Sigma  
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Trypsin                                                                                                                   Sigma  
Tween 20                                                                                                                Sigma  
xylocaine Jelly 2%                                      Astra Pharma Inc. 
xylene                                                                                                                      EMD 
 
 
ELISA kit (leptin, insulin and TNFα) 
Leptin: Goat anti-mouse leptin antibody                                       R&D Systems 
                         Recombinant rat leptin 
                         Biotinylated goat anti-mouse leptin antibody 
 
             Insulin: Mouse monoclonal insulin antibody                                   Mercodia  
                          Rat insulin standard 
                          Peroxidase conjugated mouse monoclonal anti-insulin  
 
             TNFα:  Goat anti-mouse TNFα antibody                                        Peprotech 
                           Recombinant rat TNFα 
                           Biotinylated goat anti-mouse TNFα antibody 
 
 
Goat anti- mouse collagen VI antibody                   Santa Cruz 
Peroxidase-conjugated rabbit anti goat IgG                                                          Sigma 
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